EN
Instrument Fundamentals
| Date | Close | Change | Change (%) | Open | High | Low |
|---|
News
Bleakley Financial Group LLC Has $15.34 Million Holdings in Astrazeneca Plc $AZN - Stock Observer
Hantz Financial Services Inc. Buys 39,244 Shares of Astrazeneca Plc $AZN - Stock Observer
Main Street Research LLC Makes New Investment in Astrazeneca Plc $AZN - Stock Observer
GPS Wealth Strategies Group LLC Decreases Stock Holdings in Astrazeneca Plc $AZN - Zolmax
AstraZeneca's Camizestrant: EU Approves Game-Changing Breast Cancer Pill Amid US Concerns, ETPharma
Insider Sell: Mani Sharma Sells Shares of AstraZeneca PLC
FDA Approves AstraZeneca And Daiichi's Datroway For Treating Metastatic Breast Cancer
AstraZeneca (AZN) Gains U.S. Approval for Datroway in Breast Cancer Treatment
AstraZeneca Breast Cancer Drug Recommended for Approval by EU Regulator | Morningstar
AstraZeneca, Daiichi Sankyo's Datroway Gets Approval In US For Treatment Of Breast Cancer
AZN Receives Positive EU Approval Recommendation for Enhertu
Datroway® Approved in the U.S. as First TROP2 Directed Antibody Drug Conjugate for First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates | Morningstar
AstraZeneca (AZN) Showcases Promising Clinical Data at ASCO Annual Meeting
AstraZeneca's Camizestrant Receives Positive Opinion from EMA
EU regulator recommends positive opinion of AstraZeneca's experimental breast cancer drug
Vestmark Advisory Solutions Inc. Acquires 93,186 Shares of Astrazeneca Plc $AZN - Stock Observer
Keudell Morrison Wealth Management Buys New Position in Astrazeneca Plc $AZN - Stock Observer
Astrazeneca (NYSE:AZN) Receives "Sell" Rating from Deutsche Bank Aktiengesellschaft
Deutsche Bank Aktiengesellschaft Reaffirms Sell Rating for Astrazeneca (NYSE:AZN) - Zolmax
Global Retirement Partners LLC Has $9.85 Million Stock Position in Astrazeneca Plc $AZN - Daily Political
25,822 Shares in AstraZeneca PLC $AZNCF Acquired by Burling Wealth Partners LLC - Stock Observer
How VEPPANU Approval Frames Expectations For AstraZeneca's Camizestrant In ESR1 Disease
Compugen Ltd. (NASDAQ:CGEN) Q1 2026 Earnings Call Transcript
Astrazeneca Plc (NYSE:AZN) Receives $205.33 Average Target Price from Analysts - Zolmax
Harvest Portfolios Group Inc. Sells 39,131 Shares of Astrazeneca Plc $AZN
Astrazeneca Plc $AZN Shares Acquired by Envestnet Portfolio Solutions Inc.
Gabelli Funds LLC Cuts Stock Holdings in Astrazeneca Plc $AZN - Stock Observer
Ultra-high tumor mutation burden breast cancer: genomic profiling and real-world immunotherapy results
AstraZeneca, Roche join forces to boost AI-based cancer pathology across Asia
Treatment strategies in giant cell arteritis and polymyalgia rheumatica: beyond glucocorticoids
Astrazeneca Plc $AZN Shares Acquired by ProShare Advisors LLC - Stock Observer
Northwestern Mutual Wealth Management Co. Increases Stake in Astrazeneca Plc $AZN - Daily Political
AstraZeneca (AZN) Faces Potential Market Shifts Amid Trump's Prescription Plan
AstraZeneca Wins FDA Approval for $5 Billion Blood Pressure Drug
AstraZeneca (AZN) Receives US Approval for Innovative Hypertension Treatment
AstraZeneca (AZN) Gains Approval for New Hypertension Drug Baxfendy
North American Morning Briefing: Stock Futures Slip Amid Mideast, Inflation Pessimism | Morningstar
Dow Jones Top Company Headlines at 5 AM ET: Anglo American to Sell Australian Steelmaking Coal Assets for Up to $3.875 Billion | AstraZeneca ... | Morningstar
Dow Jones Top Company Headlines at 3 AM ET: Anglo American to Sell Steelmaking Coal Assets to Dhilmar for Up to $3.875 Billion | AstraZeneca ... | Morningstar
AstraZeneca wins US approval for first-in-class blood pressure drug and expands cancer treatment Enhertu
AstraZeneca: FDA Approves Enhertu For Two New Indications
AstraZeneca's New Blood Pressure Drug Baxfendy Approved by FDA, ETPharma
AstraZeneca's blood pressure drug wins US approval
AstraZeneca Collaborates with Roche Diagnostics Asia Pacific to Help Accelerate Sustainable Ecosystem for Advanced Pathology in Breast and Lung Cancer
Sensorion Appoints Fred Chereau as Chief Executive Officer | Morningstar
New hypertension option as Astrazeneca's Baxfendy wins FDA nod | BioWorld
Supreme Court rejects Big Pharma appeals challenging negotiated drug prices in Medicare | News Express Nigeria
Ghana Hypertension Day Exposes Dangerous Treatment Gap | NewsGhana
Independent Advisor Alliance Sells 3,393 Shares of Astrazeneca Plc $AZN - Zolmax
Is It Too Late To Consider AstraZeneca (LSE:AZN) After A 34% One Year Rally?
Astrazeneca (NYSE:AZN) Earns Buy Rating from JPMorgan Chase & Co. - Daily Political
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US for two new indications for patients with HER2-positive early breast cancer
Carboplatin with or without nivolumab in metastatic triple-negative breast cancer: a randomized phase II trial
Breast Cancer Treatment from Daiichi Sankyo, AstraZeneca Approved in U.S. | Morningstar
Enhertu® Approved in the U.S. for Two New Indications for Patients with HER2 Positive Early Breast Cancer | Morningstar
AstraZeneca (AZN) Sees Leadership Changes at FDA
Bristol Myers Squibb turns to China's Hengrui to replenish pipeline
ULTOMIRIS Sales Forecast and Market Size Analysis Report 2026-2034 with Focus on United States, Germany, France, Italy, Spain, United Kingdom, and Japan
Expert recommendations for PIK3CA testing in HR+/HER2− locally advanced and metastatic breast cancer
Transforming perioperative treatment of gastro-oesophageal adenocarcinoma: triumphs, setbacks and future horizons
TR/CC CRB Excess Return Today - Live TRCCRB Index - Investing.com CA
Combined ctDNA and serum PSA for dynamic monitoring of metastatic prostate cancer starting first-line treatment: a prospective national cohort study
'Pfizer and AstraZeneca were ABANDONED, yet…': Sen Johnson drops bombshell on COVID vaccine injuries - The Economic Times Video | ET Tv
AZN Shows Promising Results in Phase III Trial for Muscle-Invasive Bladder Cancer
AZN: Promising Phase III Trial Results for Imfinzi in Bladder Cancer Treatment
AstraZeneca's Imfinzi Shows Promising Survival Benefits in Bladder Cancer Trial, ETPharma
JPMorgan Chase & Co. Reiterates Buy Rating for Astrazeneca (NYSE:AZN) - Stock Observer
AstraZeneca Says Imfinzi Combination Improved Survival In Phase III Bladder Cancer Trial
Omeros Corp (OMER) Q1 2026 Earnings Call Highlights: Strong YARTEMLEA Launch and Strategic ...
AI-powered and manual assessment of tumor-infiltrating lymphocytes in early HER2-positive breast cancer in NSABP B-41
Health: AstraZeneca's Imfinzi with pre-surgery drug boosts survival in bladder cancer trial
Maveropepimut-S, pembrolizumab and low dose cyclophosphamide in metastatic ovarian cancer: phase 1/2 PESCO trial
Ex vivo drug screening and clustering of bladder cancers for pre-clinical treatment prediction
Innate Pharma Reports First Quarter 2026 Business Update and Financial Results
Innate Pharma présente l'avancée de son portefeuille et ses résultats financiers du premier trimestre 2026
In the clinic for May 13, 2026 | BioWorld
Framework for the pharmacological treatment of obesity and its complications from the European Association for the Study of Obesity (EASO): 2026 update
Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial
Implementing AI in workflows: One step at a time
UK junior minister Miatta Fahnbulleh resigns, urges PM Starmer to set exit timetable
AstraZeneca PLC (LON:AZN) Given Consensus Recommendation of "Moderate Buy" by Brokerages - Daily Political
AstraZeneca PLC (AZN) Stock Falls as FDA Panel Votes Against New Cancer Drug
Early FMISO PET changes as exploratory predictors of immune checkpoint inhibitor response in advanced lung cancer: a pilot study
PRIMECAP Management's Strategic Moves: AstraZeneca PLC Exits with a -2.57% Impact
Cellectis Reports Financial Results for the First Quarter 2026
Cellectis publie ses résultats financiers du premier trimestre 2026
CDT Equity Advances AstraZeneca PLC (AZN)'s AZD5904 Into PCT Patent Protection Stage
Drug companies involved in TrumpRx boosted lobbying by 23% ahead of program's launch
Astrazeneca Plc $AZN Position Boosted by NewEdge Wealth LLC
Mitsubishi UFJ Asset Management Co. Ltd. Raises Holdings in Astrazeneca Plc $AZN - Stock Observer
Positron-emission tomography as a predictor of response to first-line cyclin-dependent kinase 4/6 inhibitors in patients with metastatic ER-positive HER2-negative breast cancer
5 Best Cancer Stocks to Buy for the Long Term
The microRNA inhibitor CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: a randomized phase 2 trial
Genmab A/S (0MGB) Receives a Buy from Goldman Sachs
Denali Advisors LLC Raises Stock Position in Astrazeneca Plc $AZN - Zolmax
Channel Wealth LLC Sells 10,555 Shares of Astrazeneca Plc $AZN
Astrazeneca Plc $AZN Stake Boosted by Ethic Inc. - Daily Political
AstraZeneca News
Markets.com Review 2026: Complete Account Opening Guide, Deposit, Withdrawal & Demo Test
S&P 500 Analysis: S&P 500 Trading Landscape Changes as Wall Street Reacts to Economic Data
Rivian Stock Price Prediction 2030: What South African Investors Need to Know about RIVN Stock?
AED/USD Exchange Rate Analysis: Why the AED is One of the Most Stable Currencies in Forex Right Now?
Top 10 best ETFs to invest in South Africa: Satrix 40 ETF, SYG500, STXDIV and more
Latest news
Show more
Gold Price Today, May 26: XAU/USD Holds Near $4,540 as Markets Weigh Fed Signals
Fed Leadership Change: Kevin Warsh Takes Over Federal Reserve at Critical Economic Moment
Gold Price Today, May 25: XAU/USD Opens Near $4,523 After Friday's Close at $4,509 on US-Iran Developments
Record-Breaking $500 Billion ETF Inflows in 2026: Historic Inflows Driven by US Stocks and EM Funds
Gold Price Today, May 22: XAU/USD Consolidates Near $4,520 Amid Fed Policy Uncertainty
